Home/Guides/Carbon-ion cost

Cost & candidacy

Carbon-Ion Therapy Cost in 2026: China vs Japan vs Germany

Carbon-ion radiotherapy — also called heavy-ion therapy — is the most concentrated form of radiation oncology in clinical use. Roughly fifteen centres worldwide treat patients with it, and in one of the largest markets in the world, the United States, there is not a single one. That scarcity is the first thing to understand about the price.

The second thing is that carbon-ion therapy is not “better radiotherapy for everyone.” It is a specific tool for specific tumours, and the centres that use it are selective about whom they accept. This guide sets out what treatment costs in China, Japan and Germany — the three countries with established programmes — what it involves, and the candidacy rules that determine whether it is even an option. Every figure is attributed.

Cost and access at a glance

Currency conversions use an indicative rate of about RMB 6.7 per US$1 (October 2026) and move with exchange rates. Ranges are indicative, compiled from the sources listed at the end of this page — they are not quotations. Only a written estimate from the treating centre, issued after reviewing your records, is a real price.

Why carbon-ion prices are hard to pin down

Four structural facts explain almost every confusing number you will find on this topic.

1. The equipment is extraordinarily expensive. A carbon-ion facility is a particle accelerator complex with beam transport lines, treatment rooms and shielding. Reported construction costs run into the hundreds of millions of dollars per site, and running one requires a permanent team of medical physicists and engineers. Very few institutions — or countries — can justify the investment, which keeps supply artificially low.
2. Published “prices” are rarely the same product. Some figures are hospital treatment fees. Others are all-in packages that bundle hospital fee, interpretation, accommodation, airport transfers and a companion's expenses. Placing the two side by side is how a US$30,000 treatment becomes a US$90,000 “price” online.
3. Domestic and international rates differ. China in particular publishes a domestic rate card for its own citizens, while foreign patients are quoted separately — often higher, because of the coordination, translation and scheduling involved. This is the single most common source of the “I read it was US$25,000” misunderstanding.
4. Fractionation changes the bill. Carbon-ion courses are short, but how short depends entirely on the diagnosis. An ocular melanoma may be treated in five fractions; a skull-base chordoma typically needs far more. Because most centres charge per fraction or per treatment day, the same “carbon-ion therapy” label can mean very different totals.

China: a published rate card, and the gap to what visitors pay

Where it is, and who runs it

China operates carbon-ion treatment at two institutions. The Shanghai Proton and Heavy Ion Center (SPHIC) opened in 2015 and treats both protons and carbon ions. The Wuwei Cancer Hospital heavy-ion centre in Gansu Province opened in March 2020 using a system developed by the Institute of Modern Physics of the Chinese Academy of Sciences — China's first domestically developed clinical carbon-ion system. A second campus opened in Lanzhou, the provincial capital, in 2024, and the hospital has announced further domestic carbon-ion centres in other provinces.

Wuwei is the centre we work with directly, and it is unusual in one respect that matters to anyone reading this: it publishes its fee schedule. Most centres, in every country, do not.

The published rate card

As set out on the centre's own website, carbon-ion treatment is charged per fraction for the first treatment site, with a cap:

• First treatment site: RMB 49,500 per fraction (about US$7,400)
• Course cap: RMB 198,000 for that site after four fractions (about US$29,500). From the fourth fraction onwards there is no further charge for that site.
• Each additional site: RMB 49,500, charged once only — continued treatment at that site adds nothing further.

The centre has also publicised a concessionary scheme for domestic patients in 2026, reported at RMB 49,500 for the first fraction and RMB 16,500 for each subsequent fraction, with a course cap of RMB 150,000. The two figures do not reconcile exactly, which is itself a useful illustration of the point: the number that matters is the one in your written quotation, not the one on the website.

A published comparison worth knowing about

For one specific tumour type — ocular (uveal) melanoma, where carbon ion is used to save the eye rather than remove it — the Wuwei centre has published its own cost comparison: a five-fraction course there costs about RMB 130,000 (roughly US$19,400), including planning and basic follow-up, against roughly RMB 250,000–300,000 the centre attributes to Japan, about RMB 300,000 to Shanghai, and RMB 500,000–600,000 to Germany. Those comparative figures are the centre's own characterisation, not an independent audit, and the Japanese and German numbers may reflect different fractionation or package definitions. But they illustrate the order of magnitude, and the fact that a short course dramatically changes the total.

Insurance inside China

Carbon-ion treatment itself is not covered by China's national medical insurance. Other inpatient costs can be, and for Chinese patients several major insurers sell dedicated “carbon-ion” policies that reimburse treatment at Wuwei and Lanzhou. International patients should assume self-pay and, if they hold an international policy, confirm coverage in writing before travelling.

Japan and Germany: mature programmes, higher quotes

Japan

Japan pioneered clinical carbon-ion therapy and still operates the largest number of facilities — seven as of late 2025, led by the long-established programme at the National Institute of Radiological Sciences. For Japanese residents, some indications are covered by national health insurance. For international patients there is no standard published rate, and quotes commonly fall in the US$70,000–120,000 band for a full course, depending on the centre, the diagnosis and how many fractions are required.

Japan's advantage is depth of experience: more accumulated patient-years with carbon ions than anywhere else. Its disadvantage, for a foreign patient, is waiting time — several established centres report scheduling measured in months — and a pricing process that is opaque from outside the country.

Germany

Europe's reference centre is the Heidelberg Ion-Beam Therapy Center (HIT), operating since 2009, with a second carbon-ion facility elsewhere in the country. International patient quotes are comparable to Japan's, in the US$70,000–120,000 range, with some published estimates higher. Germany's statutory health insurance does not cover visitors, so international patients at HIT are self-pay.

The United States: not an option yet

As of 2026, carbon-ion therapy is not clinically available in the United States. This is not a regulatory accident: the technology requires a facility costing hundreds of millions of dollars, and no US institution has yet commissioned one for routine clinical use.

That is changing. Mayo Clinic in Jacksonville, Florida is building the first clinical carbon-ion centre in the Western Hemisphere, in partnership with Hitachi. The proton component is expected to begin treating patients in 2027, with carbon-ion treatment anticipated in 2028, initially through clinical trials for aggressive and treatment-resistant cancers. Florida announced in early 2026 that it would be the first US state with a carbon-ion programme.

Two things are worth saying together, because it is easy to read a statement like that as a sales pitch. First, the United States has world-class conventional and proton radiotherapy, and for most patients that is where treatment starts. Second, carbon ion's clearest evidence base is in a narrow set of tumours — it is not a general-purpose upgrade.

For scale, US self-pay ranges for proton therapy for comparable indications are commonly estimated at US$80,000–150,000 for a full course, against roughly US$30,000–60,000 for proton therapy in China. That gap is a genuine part of why patients travel.

What sits outside the treatment price

Whatever centre you approach, the headline figure is only part of the budget. Carbon-ion courses are short, but the surrounding process is not. Ask any provider to confirm in writing which of the following are included:

• Pre-treatment imaging and assessment — PET-CT or MRI, pathology review, and any repeat biopsy the centre requires.
• Simulation, immobilisation and treatment planning — a custom mask or body mould plus physicist-led planning, typically one to two weeks before the first fraction. This is the part patients most often underestimate.
• Each fraction delivered, if you are billed per session rather than per course.
• Inpatient stay, which varies from outpatient-style visits to short admission depending on the site treated.
• Travel and accommodation for roughly three to five weeks, plus a companion.
• Oral and dental assessment for head and neck cases — infections and untreated teeth should be dealt with before treatment begins.
• Interpretation and coordination, if not bundled.
• Follow-up imaging at roughly 3, 6 and 12 months, which can usually be done at home with images sent back to the treating centre.
• Re-irradiation, in cases where the team anticipates or later recommends a second course.

Who is actually eligible

Carbon-ion therapy is not “the strongest radiotherapy” that can be applied to any tumour. Its published evidence base is concentrated in tumours that respond poorly to conventional radiation, or that sit too close to critical structures for conventional radiation to be delivered safely.

Where the evidence is strongest:

• Skull-base and spinal chordoma and chondrosarcoma
• Adenoid cystic carcinoma of the head and neck, trachea and salivary glands
• Ocular (uveal) melanoma, where the aim is to preserve the eye
• Recurrent head and neck or nasopharyngeal cancer after previous radiotherapy, where re-irradiation with photons is hazardous
• Bone and soft-tissue sarcomas, including inoperable cases

Actively studied, with less settled evidence:

• Prostate cancer, particularly hypofractionated courses
• Pancreatic cancer and unresectable liver tumours
• Early-stage lung cancer, especially in patients who cannot undergo surgery

Generally not candidates:

• Blood cancers such as leukaemia and lymphoma — there is no single target for a beam
• Widespread metastatic disease
• Cases in which conventional intensity-modulated radiotherapy would achieve equivalent outcomes at a fraction of the cost — a good centre will tell you this directly

Centres also expect that the disease is localised, that you can hold a stable position for treatment, that the tumour's relationship to critical structures is workable, and that organ function is adequate. Previous radiotherapy does not automatically disqualify you — re-irradiation is one of the main reasons carbon ion is considered — but it requires a cumulative dose assessment and a candid discussion of toxicity risk.

Carbon ion or proton? A short answer

Patients ask this constantly, and the honest answer is that for most cancers proton therapy is sufficient, more widely available and considerably cheaper. Carbon ions are heavier and cause denser, harder-to-repair DNA damage: their relative biological effectiveness is roughly two to three times that of photons, against about 1.1 times for protons. For a radioresistant histology, that difference matters.

Published series in skull-base chordoma put five-year local control in the region of 70–85% for carbon ion versus 60–75% for proton therapy. The gap is real but modest, and it is not a reason to choose carbon ion for a tumour where the two perform comparably. Carbon-ion courses are also shorter — often 4 to 16 fractions against 20 to 35 for conventional radiotherapy — which matters if you are travelling.

The practical rule: if your tumour type appears in the list above, ask whether carbon ion has a dosimetric or biological advantage in your case. If it does not appear there, proton therapy or high-precision photon radiotherapy is more likely to be the appropriate discussion.

Frequently asked questions

Is carbon-ion therapy available in the United States?

No. As of 2026 there is no clinically operating carbon-ion facility in the United States. Mayo Clinic in Jacksonville, Florida is building the first in the Western Hemisphere; proton therapy is expected there in 2027 and carbon-ion treatment in 2028, initially through clinical trials. American patients who need carbon ions today travel to Asia or Europe.

What does a carbon-ion course cost in China?

Wuwei Cancer Hospital publishes a domestic rate card of RMB 49,500 for the first fraction, capped at RMB 198,000 per course at a single treatment site, with each additional site charged once at RMB 49,500 — roughly US$7,400, US$29,500, and US$7,400 respectively. Foreign patients are usually quoted above the domestic rate; published industry estimates for an international course sit around US$40,000–60,000. Insist on a written, itemised quotation issued after your records have been reviewed.

Is carbon-ion therapy covered by insurance?

Rarely, for international patients. In China the carbon-ion treatment itself sits outside the national insurance scheme, though other inpatient costs may be reimbursable and domestic patients can use commercial “carbon-ion” policies sold by major insurers. In Japan some indications are covered for residents. Germany's statutory system does not cover visitors. Unless your insurer confirms coverage in writing, plan for self-pay.

How long will I need to stay?

Longer than the treatment itself suggests. The delivery is short — commonly 4 to 16 fractions over one to four weeks, sometimes fewer — but simulation, immobilisation and physicist-led planning typically add one to two weeks beforehand. Plan on roughly three to five weeks on site, including assessment, treatment and early follow-up.

Is carbon-ion therapy better than proton therapy?

Not in general — it is different. Carbon ions have a higher relative biological effectiveness, which matters most for radioresistant histologies such as chordoma, chondrosarcoma and adenoid cystic carcinoma. For many other tumours, including most paediatric cases, proton therapy remains the standard choice and is far more widely available. Which is appropriate is a clinical decision for the treating team, not a preference to be chosen from a price list.

Sources

• Gansu Wuwei Heavy Ion Center — official fee schedule published on the centre's website, 2026: RMB 49,500 per fraction for the first treatment site; RMB 198,000 cap after four fractions; RMB 49,500 for each additional site, charged once.
• Gansu Wuwei Heavy Ion Center — official centre and clinical information: domestically developed carbon-ion system (Institute of Modern Physics, Chinese Academy of Sciences); treated-patient volume; 40-plus tumour types.
• Benliu News (Gansu provincial media), May 2026 — fifth-anniversary concessionary pricing reported at RMB 49,500 for the first fraction, RMB 16,500 for subsequent fractions, and a RMB 150,000 course cap.
• Gansu Wuwei Heavy Ion Center — published cost comparison for ocular melanoma: approximately RMB 130,000 for a five-fraction course, compared by the centre with Japan (RMB 250,000–300,000), Shanghai (about RMB 300,000) and Germany (RMB 500,000–600,000).
• CancerFax, Carbon Ion Therapy Cost Abroad (updated September 2026) — country-level indicative cost ranges and global facility counts.
• ChinaMedAccess, China Proton and Heavy Ion Therapy Network Expansion 2026 — international-patient pricing bands by fractionation and modality.
• MedChinaGo, How International Patients Get Proton & Heavy Ion Therapy in China — centre comparison, cumulative patient volumes, and candidate / non-candidate indications.
• Mayo Clinic and CancerConnect, 2025–2026 — first clinical carbon-ion centre in the Western Hemisphere, Jacksonville; proton therapy expected 2027, carbon-ion treatment 2028 through clinical trials.
• Published Japanese and European clinical series, as summarised in peer-reviewed reviews (Cancer Treatment Reviews, 2020 onwards) — five-year local control for skull-base chordoma with carbon ion versus proton therapy.
• Reporting on China's national particle-therapy equipment planning — proton and carbon-ion units planned under the 14th Five-Year Plan, with further domestic centres announced in Zhejiang, Wuhan and Fujian for 2025–2026.

This guide is published for general information and is not medical advice, a diagnosis, or a recommendation for any particular treatment or facility. Cost figures are indicative planning ranges compiled from the sources listed above, not quotations, and they change. Carbon-ion therapy is appropriate only for specific indications and only a treating medical team can determine eligibility. OncoBridge provides information and facilitation services; it does not provide medical care and does not guarantee any clinical outcome.